Why the Definition Varies — and Why Clinicians State the One They Are Using
Recurrent implantation failure (RIF) is the clinical scenario in which embryos judged suitable for transfer repeatedly fail to implant over the course of assisted reproductive technology (ART) treatment, to a degree no longer plausibly explained by chance for that individual patient. It is a descriptive label attached to a treatment history rather than a disease entity in its own right, and — unusually for a term used this freely in reproductive medicine — it has no single, universally agreed definition.
For roughly two decades, the reproductive-medicine literature defined RIF by counting: a fixed number of failed embryo transfers, or a cumulative number of embryos transferred without implantation, sometimes adjusted for maternal age or for whether transfers took place at cleavage or blastocyst stage. The difficulty, documented repeatedly in reviews indexed on PubMed, is that those thresholds differed from publication to publication. The same treatment history could satisfy one paper's definition of RIF and fall short of another's — which made prevalence estimates inconsistent, trial populations heterogeneous and, most practically, the decision to open a diagnostic work-up arbitrary.
ESHRE's 2023 good-practice recommendations took a different approach. The working group describes RIF as a phenomenon that exists only in the context of ART — it is defined by what happens after embryo transfer, not by any property of the patient in isolation — and recommends an individualised assessment: rather than applying one count to every patient, clinicians are asked to consider the cumulative predicted likelihood of implantation for that particular patient across the transfers performed to date, and to reach for the RIF label only when repeated failure exceeds what that individual picture would explain. The recommendations set out the working group's reasoning and suggested thresholds in full; this article deliberately describes the guidance qualitatively, because the source document — not a summary of it — is what clinicians should apply in practice.
The definitional question is not academic housekeeping. The definition is the gate to the work-up. Draw it too loosely and clinicians over-investigate — and over-investigation, in this field, feeds directly into the market for unproven add-on tests. Draw it too rigidly and a patient whose individual prognosis makes repeated failure genuinely surprising waits longer than necessary for a structured review. Trainees are therefore taught a habit that sounds bureaucratic and is not: record which definition was applied, and why, before any test is ordered.
The Four-Domain Diagnostic Framework
Once the label is justified, the assessment trainees learn is organised across four domains: the embryo, the endometrium and uterine cavity, maternal and systemic factors, and the male factor. Few of the individual investigations are exotic. The discipline lies in the sequence, in attributing each finding to its evidence base, and in documenting negative findings with the same care as positive ones — because in RIF, the absence of an abnormality is itself clinically meaningful information.
Embryo Factor
The first structured question is whether the embryos transferred were as competent as their grading suggested. Morphological grading is a useful but imperfect proxy for developmental potential — a limitation examined in more detail in our clinician overview of embryo grading and selection — so trainees are taught to treat the embryology record as primary evidence: fertilisation checks, cleavage timings, blastulation, the culture environment, and the laboratory's key performance indicators over the relevant period.
Embryo aneuploidy is a recognised contributor to implantation failure, particularly with advancing oocyte age, as described consistently across the peer-reviewed literature. The role of preimplantation genetic testing for aneuploidy within a RIF work-up, by contrast, remains debated, and ESHRE's recommendations treat it as an option to be weighed and counselled case by case rather than a default response. The embryo-factor review is also where clinical and laboratory reasoning meet, which is why a credible RIF assessment is multidisciplinary by construction: the clinician cannot complete this domain without the embryologist, and vice versa.
Endometrial and Uterine Assessment
The second domain examines the environment into which transfer occurred. The anatomical questions come first: transvaginal ultrasound, saline-infusion sonography and, where indicated, hysteroscopy are used to assess the cavity for polyps, submucosal fibroids, intrauterine adhesions and uterine anomalies, with imaging of the adnexa for hydrosalpinges — findings the peer-reviewed literature has long associated with impaired implantation.
Chronic endometritis is assessed histologically, typically with plasma-cell markers such as CD138, although the diagnostic criteria themselves remain a live debate in the literature, and trainees are taught to say so rather than to present the diagnosis as settled. The functional question — whether the window of implantation is displaced in time for a given patient — is conceptually attractive, but transcriptomic endometrial receptivity testing remains investigational, and ESHRE's recommendations counsel against presenting it as an established component of routine assessment.
Maternal and Systemic Factors
The third domain widens the lens to the patient as a whole. An endocrine review — thyroid function in particular — and attention to modifiable exposures such as smoking and body-mass index are grounded in implantation biology described in the peer-reviewed literature.
Two frequently requested families of tests sit differently. Thrombophilia screening is not supported as a routine RIF investigation in the absence of an independent clinical indication, a position reflected in both ESHRE guidance and ASRM practice documents. Immunological testing — peripheral natural killer cell quantification, cytokine ratios and related panels — is placed by ESHRE's recommendations outside routine care and within the research setting, because the assays lack the standardisation and demonstrated clinical utility that routine use would require. Trainees learn to treat declining such a test, with the reasoning explained, as an evidence-based clinical act rather than an omission.
Male Factor
The fourth domain is the one a work-up can quietly omit, and trainees are taught not to omit it. A formal semen assessment is re-examined rather than assumed from the original work-up, and modifiable male exposures are reviewed alongside it.
Sperm DNA fragmentation testing occupies the same contested territory as several endometrial investigations: assays exist and are widely marketed, but their clinical utility in this context is debated in the peer-reviewed literature, and ASRM practice documents caution against routine use. The framework's instruction is consistent across all four domains: name the evidence when a test is offered, and name it when a test is declined.
Add-On Tests: The Cautions Clinicians Are Trained to Attribute
RIF sits at the centre of the ART add-on debate, because patients presenting with it are, understandably, receptive to any test framed as an answer — which places a specific counselling responsibility on the clinician. ESHRE's 2023 recommendations reviewed the tests and interventions commonly offered under the RIF label and concluded that many lack sufficient evidence for routine use; ASRM committee documents have reached similar conclusions on immunological testing and on several other adjuncts. Both organisations grade the evidence claim by claim in the source documents, and — as throughout this article — the grading should be read there rather than paraphrased into false precision.
From that guidance, trainees are taught three working disciplines. First, attribute before ordering: every proposed investigation is tied to a named evidence source and its stated strength, in the record as well as in the consultation. Second, separate research from routine: investigational tests belong in research settings or explicitly labelled contexts, not in a standard diagnostic pathway. Third, counsel without implying resolution: offering an unproven test must never be allowed to suggest that it will convert uncertainty into an actionable answer, because in the current evidence base it may not.
The same discipline extends to the adjunct interventions marketed alongside such tests. The structured framework exists precisely so that the clinical response to repeated failure is reasoning, not a menu.
From Label to Assessment: How the Reasoning Is Sequenced
In training, the framework is rehearsed as a sequence. Its product is not a promised answer; it is a defensible, documented line of reasoning that the clinical team, and the patient, can see was applied in full.
- Verify the label: does this treatment history meet the stated definition, individualised to this patient?
- Convene the review: prior cycles are re-examined jointly by clinician and embryologist, because half of the evidence lives in the laboratory record.
- Work the four domains in order, attributing each positive and negative finding as it is documented.
- Distinguish findings with an evidence-based management pathway from findings whose significance is uncertain — and say which is which in the record.
- Counsel honestly: a proportion of structured assessments end without an identified explanation, and the peer-reviewed literature is candid about this.
Continuing Your Reproductive-Medicine Education
The RIF framework rewards exactly the kind of study that cannot be rushed: definitional precision, systematic domain-by-domain reasoning, and the professional discipline of attributing every claim — including the negative ones — to named evidence. It is a discipline that consolidates through supervised work on real case material, alongside the clinicians and embryologists who hold the records.
Clinicians who want to rehearse that reasoning in a structured setting can review the fine-ART Masterclass, a two-day, case-based training programme delivered with Centrum Clinic in Ankara for physicians and embryologists, in which participants work through real cases under supervision and the diagnostic framework described here is examined in practice.